Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed

New Biosimilar User Fees Are Announced By FDA

 
• By Derrick Gingery
  
Workload
Meetings and manufacturing supplements are estimated to rise in FY 2022, while one less biosimilar application is expected, compared to the current fiscal year. • Source: Alamy

More from Biosimilars

More from Products